Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $143,000 with net income of −$130M.
Q3 2025 key financials · XBRL
- Revenue
- $143,000
- −86.1% QoQ
- Net income
- −$130M
- −69.3% YoY · −12.5% QoQ
- Operating margin
- -99710.5%
- EPS (diluted)
- −$1.39
- −44.8% YoY · −13.0% QoQ
Source: XBRL data from the Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 10-Q on SEC EDGAR. USD.
Crinetics Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors this quarter; risks consistent with prior 10-K disclosures
- Most materially updated risk: increased operating losses due to PALSONIFY U.S. approval and EMA submission pre-commercialization activities
- Regulatory risk: reliance on successful FDA approval and pending EMA regulatory approval for PALSONIFY and other late-stage candidates
- Operational risk: commercial success hinges on market acceptance by physicians, patients, and payors of PALSONIFY
- Financial risk: accumulated deficit of $1.3 billion as of September 30, 2025, with expected substantial increases in operating losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Crinetics Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.